相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- A comprehensive meta-analysis of 53 studies involving over 8.4 million postmenopausal women found that starting hormone replacement therapy within five years of menopause onset reduces Alzheimer's disease risk by 32%. - Women who began hormone therapy at age 65 or older showed a 38% increased risk of developing Alzheimer's disease, particularly when treatment included progestin. - The findings suggest a critical window hypothesis where early hormone therapy may protect brain function during the neurological transition of menopause, but starting too late may be counterproductive. - Researchers emphasize that while the data is promising, more rigorous clinical trials are needed to establish definitive guidelines for hormone therapy timing and formulations.
- A late-stage ALS patient treated with Trethera's investigational drug TRE-515 under FDA's Expanded Access program showed disease stabilization over three months, with improvements in vital capacity and functional rating scales. - TRE-515, which targets the enzyme deoxycytidine kinase in the nucleoside salvage pathway, demonstrated a favorable safety profile with no adverse events reported during the treatment period. - This marks the first clinical use of TRE-515 beyond cancer applications, potentially opening new treatment avenues for ALS patients who have limited FDA-approved options.
